772.418.6302

Call Us For More Information

Leadership

Vycellix Founding Board of Directors

CEO & Chairman of the Board

Evren Alici, M.D., Ph.D.

Dr. Alici serves as Head, Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and as a Visiting Research Professor at the NSU Cell Therapy Institute at Nova Southeastern University, Ft. Lauderdale, Fla.

Dr. Alici received his M.D. degree from Ege University, Faculty of Medicine, Izmir, Turkey, and his Ph.D. in Hematology from the Karolinska Institutet in Stockholm, Sweden. He did postdoctoral research as a molecular biologist at Karolinska University Hospital, Huddinge. He is Vice President of the Swedish Society of Gene and Cell Therapy, and a member of the European Group for Blood and Marrow Transplantation, the Nordic Blood and Marrow Transplantation Society, Nordic Myeloma Study Group, the American Society of Hematology, and the European Society of Gene and Cell Therapy. Dr. Alici’s translational research in cell and gene therapy focuses on human NK-cells. He has published numerous related articles and holds patents in large-scale expansion of primary human NK-cells.

Chief Medical Officer

Hans-Gustaf Ljunggren, M.D., Ph.D.

Dr. Ljunggren is the former Dean of Research, Karolinska Institutet, former Director of the Center for Infectious Medicine, Department of Medicine, Karolinska University Hospital in Huddinge, Sweden, and former Scientific Secretary of the Swedish Cancer Society, and currently serves as a Professor at Karolinska Institutet.

Dr. Ljunggren received his M.D. and Ph.D. degrees from Karolinska Institutet. He did his post-doctoral research at the Massachusetts Institute of Technology. In 2001, he was appointed professor of infectious medicine at the Department of Medicine at Karolinska Institutet and Founding Director of the Centre for Infectious Medicine (CIM) at Karolinska Institutet. In 2013, Dr. Ljunggren was appointed Dean of Research at Karolinska Institutet. His research field in immunology is mainly focused on early immune reactions in infectious and malignant disease. He has had a long-term interest in exploring the molecular specificity and function of human NK-cells in health and in different disease settings.

President

Douglas W. Calder

Mr. Calder is the former Director of Development & Strategic Planning at the NSU Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, Florida, and continues to serve the NSU research mission in the role as strategic advisor.

A graduate of Florida State University, Mr. Calder has nearly 25-years of life science executive experience, with an emphasis on investor relations, capital markets strategies and public/media relations, having served in various senior executive and officer roles for Florida-based biotechnology companies and research institutes including Viragen, Inc., Accentia Biopharmaceuticals, Inc., Biovest International, Inc., and the Vaccine & Gene Therapy Institute of Florida, as well as having formerly served as a licensed registered representative financial portfolio manager with a focus on life science equities with the NYSE-member firms, Gruntal & Co. and Dean Witter Reynolds. Mr. Calder recently served on the Board of Directors of BioFlorida.

Executive Vice President, General Counsel

Samuel Duffey, Esq.

As a former attorney for the U.S. Securities and Exchange Commission (SEC), Mr. Duffey has practiced corporate, business and securities law for more than 30-years. Mr. Duffey earned a Bachelor of Science degree in Business Administration and a degree of Doctor of Jurisprudence with Honors from Drake University. Mr. Duffey is the CEO of ViraCell Advanced Products, LLC, a Texas company collaborating with the Texas A&M Center for Innovation in Advanced Manufacturing to develop innovative bioreactor production systems and vaccines for emerging infectious diseases. Until July 2013, Mr. Duffey served as President & CEO of Biovest International, a public biotech company that is developing novel cancer vaccine and cell culture technology developed in partnership with the National Cancer Institute. Previously, Mr. Duffey was general counsel of numerous biotech companies and served as President and CEO of Accentia Biopharmaceuticals, Inc. During his career, Mr. Duffey has started and served as a member of management of numerous companies, including Invisa, Inc., a public company engaged in the manufacture of proprietary safety products and textured coatings, including for the auto industry.

Executive Vice President, Intellectual Property Officer

Michael J. Keller, J.D.

Michael J. Keller, J.D. has practiced intellectual property law in the life sciences for over 25 years. He earned his BS in biology and his Juris Doctor from the University of Georgia. Mr. Keller is the founder of Keller Life Science Law, a boutique firm specializing in assisting life science companies to protect and develop biomedical technologies. Previously he founded the patent department for IVAX Corporation and later served as Chief Patent Counsel to GMP Companies. Prior to founding his own firm he held partner level positions in an AMLAW 250 general practice firm and well as with two intellectual property boutiques. Mr. Keller started his career in technology transfer first with the Department of Energy and later with the National Cancer Institute.

Distinguished Vycellix Non-Board Founders Include:

  • Richard Jove, Ph.D
    Institute Director, NSU Cell Therapy Institute at Nova Southeastern University, Florida
  • Adil Doganay Duru, Ph.D.
    Assistant Professor, NSU Cell Therapy Institute, Nova Southeastern University, Florida
  • Tolga Sütlü, Ph.D.
    Research Group Leader, Nanotechnology Research and Application Center & Assistant Professor, Molecular Biology, Genetics and Bioengineering Program of the Faculty of Engineering and Natural Sciences, Sabanci University, Turkey
  • Hareth Nahi, M.D., Ph.D.
    Physician Specialist, Internal Medicine and Hematology and Senior Researcher at Karolinska Institutet University Hospital, Department of Medicine, Sweden

Comments are closed.